PAVmed Beheer

Beheer criteriumcontroles 3/4

De CEO PAVmed is Lishan Aklog, benoemd in Jun2014, heeft een ambtstermijn van 10.42 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 953.20K, bestaande uit 95.8% salaris en 4.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 3.61% van de aandelen van het bedrijf, ter waarde $ 388.98K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.2 jaar en 9.8 jaar.

Belangrijke informatie

Lishan Aklog

Algemeen directeur

US$953.2k

Totale compensatie

Percentage CEO-salaris	95.8%
Dienstverband CEO	10.4yrs
Eigendom CEO	3.6%
Management gemiddelde ambtstermijn	2.2yrs
Gemiddelde ambtstermijn bestuur	9.8yrs

Recente managementupdates

Recent updates

PAVmed Continues To Have Lots Of Potential But EsoGuard Determines Short-Term Progress

Jul 05

Start Accumulating PAVmed

Dec 24

We Think PAVmed (NASDAQ:PAVM) Can Afford To Drive Business Growth

Sep 02

PAVmed: Long Term Investment Case Remains Despite Weak Q2

Aug 23

PAVmed: A True Game-Changer For Medical Device Innovation

Jun 14

PAVmed forms digital health company, Veris Health

Jun 02

PAVmed's subsidiary receives CE mark for EsoCheck esophageal cell collection device

May 26

PAVmed (NASDAQ:PAVM) Is In A Good Position To Deliver On Growth Plans

May 19

PAVmed drops 14% on launch of $13.4M direct offering

Jan 06

PAVmed closes additional direct offering of common stock

Dec 22

Do Institutions Own PAVmed Inc. (NASDAQ:PAVM) Shares?

Dec 16

PAVmed offers stock for $8.9M

Dec 11

PAVmed EPS beats by $0.02

Nov 17

There Is Progress At PAVmed, But More Patience Is Required

Oct 30

Analyse CEO-vergoeding

Hoe is Lishan Aklog's beloning veranderd ten opzichte van PAVmed's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$67m
Mar 31 2024	n/a	n/a	-US$71m
Dec 31 2023	US$953k	US$913k	-US$66m
Sep 30 2023	n/a	n/a	-US$71m
Jun 30 2023	n/a	n/a	-US$79m
Mar 31 2023	n/a	n/a	-US$90m
Dec 31 2022	US$1m	US$901k	-US$89m
Sep 30 2022	n/a	n/a	-US$86m
Jun 30 2022	n/a	n/a	-US$72m
Mar 31 2022	n/a	n/a	-US$58m
Dec 31 2021	US$9m	US$583k	-US$51m
Sep 30 2021	n/a	n/a	-US$42m
Jun 30 2021	n/a	n/a	-US$35m
Mar 31 2021	n/a	n/a	-US$30m
Dec 31 2020	US$1m	US$431k	-US$35m
Sep 30 2020	n/a	n/a	-US$32m
Jun 30 2020	n/a	n/a	-US$30m
Mar 31 2020	n/a	n/a	-US$28m
Dec 31 2019	US$890k	US$431k	-US$17m
Sep 30 2019	n/a	n/a	-US$17m
Jun 30 2019	n/a	n/a	-US$17m
Mar 31 2019	n/a	n/a	-US$19m
Dec 31 2018	US$772k	US$346k	-US$19m
Sep 30 2018	n/a	n/a	-US$12m
Jun 30 2018	n/a	n/a	-US$14m
Mar 31 2018	n/a	n/a	-US$10m
Dec 31 2017	US$444k	US$297k	-US$10m

Compensatie versus markt: De totale vergoeding ($USD 953.20K ) Lishan } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 653.16K ).

Compensatie versus inkomsten: De vergoeding van Lishan is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Lishan Aklog (58 yo)

10.4yrs

Tenure

US$953,200

Compensatie

Dr. Lishan Aklog, M.D., serves as Executive Chairman at Veris Health Inc. since April 2023. He served as Independent Director at ContraFect Corporation since June 14, 2020 until December 04, 2023. Dr. Aklo...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Lishan Aklog	Chairman & CEO	10.4yrs	US$953.20k	3.61% $ 389.0k
Dennis McGrath	President & CFO	7.7yrs	US$673.50k	0.49% $ 52.6k
Shaun O'Neill	Executive VP & COO	2.8yrs	US$498.00k	0.17% $ 18.6k
Michael Gordon	Executive VP	2.5yrs	US$710.50k	0% $ 0
Brian deGuzman	Executive VP	1.6yrs	US$593.10k	0% $ 0
Suman Verma	Senior VP of Molecular Genetics & Chief Scientific Officer	1.8yrs	geen gegevens	geen gegevens
Michael Parks	Vice President of Investor Relations	no data	geen gegevens	geen gegevens
Deepika Lakhani	Senior VP	1.8yrs	geen gegevens	geen gegevens
Victoria Lee	Senior VP & Chief Medical Officer	1.8yrs	geen gegevens	geen gegevens

2.2yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van PAVM wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.2 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Lishan Aklog	Chairman & CEO	10.4yrs	US$953.20k	3.61% $ 389.0k
Ronald Sparks	Independent Director	9.8yrs	US$251.90k	0.62% $ 67.3k
Todd Rosengart	Member of Medical Advisory Board	10yrs	geen gegevens	geen gegevens
Timothy Baxter	Independent Director	3.4yrs	US$238.90k	0.62% $ 67.3k
Marc Gerdisch	Member of Medical Advisory Board	10yrs	geen gegevens	geen gegevens
Philip Stieg	Member of Medical Advisory Board	9.8yrs	geen gegevens	geen gegevens
Albert Chin	Member of Medical Advisory Board	9.8yrs	geen gegevens	geen gegevens
Michael Glennon	Independent Vice Chairman	10.1yrs	US$228.90k	0.78% $ 84.5k
Timothy Murphy	Member of Medical Advisory Board	10yrs	geen gegevens	geen gegevens
Debra White	Independent Director	3.6yrs	US$248.90k	0.62% $ 67.3k
Christopher Hartnick	Member of Medical Advisory Board	8yrs	geen gegevens	geen gegevens
Daniel Engelman	Member of Medical Advisory Board	7.1yrs	geen gegevens	geen gegevens

9.8yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van PAVM wordt beschouwd als ervaren (gemiddelde ambtstermijn 9.8 jaar).

PAVmed Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Insufficient new directors

Pavmed Inc. Appoints Dennis Matheis to Board of Directors

PAVmed Inc., Annual General Meeting, Jun 20, 2024

Independent Vice Chairman recently bought US$161k worth of stock

PAVmed Inc., Annual General Meeting, Jun 21, 2022

PAVmed Inc. Appoints Shaun O’Neil as Executive Vice President and Chief Operating Officer

Recent updates

Consensus revenue estimates decrease by 11%, EPS upgraded

PAVmed Provides Update on Nasdaq Staff Determination Letter Regarding Non-Compliance with Market Value Under Listing Rule 5550(b)(2)

Consensus revenue estimates decrease by 16%, EPS upgraded

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Lucid Diagnostics Announces Positive Data from Its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of Esoguard Esophageal Precancer Testing in A Screening Population

Insufficient new directors

New major risk - Market cap size

Consensus EPS estimates fall by 13%, revenue upgraded

Price target decreased by 21% to US$13.00

Pavmed Inc. Appoints Dennis Matheis to Board of Directors

PAVmed Inc., Annual General Meeting, Jun 20, 2024

Consensus revenue estimates decrease by 28%, EPS upgraded

Price target decreased by 21% to US$16.38

Full year 2023 earnings: EPS exceeds analyst expectations

PAVmed Inc. Launches Incubator to Advance Existing Pipeline Technologies including PortIO, EsoCure and CarpX

PAVmed Receives Notice from Nasdaq Regarding Non-Compliance with the Market Value of the Company’s Listed Securities Under Nasdaq Listing Rule 5550(b)(2)

New major risk - Share price stability

Are Investors Undervaluing PAVmed Inc. (NASDAQ:PAVM) By 28%?

Now 24% undervalued after recent price drop

Lucid Diagnostics Inc. and Pavmed Inc. Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies

Price target decreased by 48% to US$20.63

Pavmed Inc. Releases Positive Data from First Prospective Clinical Utility Study of EsoGuard® Esophageal Pre Cancer Detection

Consensus revenue estimates decrease by 12%

New major risk - Negative shareholders equity

PAVmed Receives 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement

Consensus revenue estimates increase by 35%

Consensus revenue estimates decrease by 40%, EPS upgraded

Consensus revenue estimates increase by 33%

No longer forecast to breakeven

PAVmed Receives A Notice from Nasdaq Regarding Minimum Bid Price Requirement

Independent Vice Chairman recently bought US$161k worth of stock

Price target decreased to US$5.06

Consensus forecasts updated

Consensus forecasts updated

Consensus revenue estimates fall by 80%

Price target decreased to US$5.50

Is PAVmed (NASDAQ:PAVM) Using Debt In A Risky Way?

PAVmed Non-GAAP EPS of -$0.17 beats by $0.03

PAVmed Continues To Have Lots Of Potential But EsoGuard Determines Short-Term Progress

PAVmed Inc.(NasdaqCM:PAVM) dropped from Russell 2000 Dynamic Index

PAVmed Inc., Annual General Meeting, Jun 21, 2022

PAVmed Inc. announced delayed annual 10-K filing

Consensus revenue estimates fall by 10%

Price target decreased to US$8.13

PAVmed Inc. Appoints Shaun O’Neil as Executive Vice President and Chief Operating Officer

PAVmed Inc. Appoints Joan Harvey to Its Board of Directors

Start Accumulating PAVmed

Consensus forecasts updated

Price target increased to US$9.50

We Think PAVmed (NASDAQ:PAVM) Can Afford To Drive Business Growth

PAVmed: Long Term Investment Case Remains Despite Weak Q2

Consensus revenue estimates fall to US$1.02m

Independent Director David Battleman has left the company

Independent Director David Weild has left the company

PAVmed: A True Game-Changer For Medical Device Innovation

Consensus forecasts updated

PAVmed forms digital health company, Veris Health

PAVmed's subsidiary receives CE mark for EsoCheck esophageal cell collection device

Data Presented at Digestive Disease Week 2021 Support Clinical Utility of PAVmed Subsidiary Lucid Diagnostics’ EsoCheck and EsoGuard Technologies

PAVmed (NASDAQ:PAVM) Is In A Good Position To Deliver On Growth Plans

Consensus forecasts updated

PAVmed Inc. has completed a Follow-on Equity Offering in the amount of $41.576088 million.

Price target raised to US$6.42

First U.S. Patient Undergoes Successful Minimally Invasive Carpal Tunnel Release Using PAVmed’s CarpX® Device

New 90-day high: US$2.68

PAVmed Inc. has completed a Follow-on Equity Offering in the amount of $13.44 million.

PAVmed drops 14% on launch of $13.4M direct offering

New 90-day high: US$2.13

PAVmed Inc. has completed a Follow-on Equity Offering in the amount of $8.1 million.